Overproduction of growth hormone in acromegaly can result in a cardiomyopathy. Control of the underlying disease results in control of the heart disease. Failure to control progression of the cardiac disease increases morbidity and mortality.
Risk factors for cardiomyopathy:
(1) long duration of disease
(2) active, uncontrolled disease
Clinical features:
(1) tachycardia
(2) hypertension
(3) left ventricular hypertrophy followed by biventricular dilatation (dilated cardiomyopathy)
(4) heart failure
Structural Changes |
Cardiac Output |
Functional Status |
Stage |
none apparent |
high (increased contractility, low vascular resistance) |
asymptomatic |
early hyperkinetic |
myocardial hypertrophy, interstitial fibrosis, mucin deposits |
diastolic dysfunction |
dyspnea on exertion |
intermediate |
ventricular dilatation |
low with systolic dysfunction and heart failure |
dyspnea at rest |
late and end-stage |
Additional cardiac disorders in acromegaly:
(1) valvular disease
(2) cardiac arrhythmias
(3) coronary artery disease with myocardial ischemia or infarction
Purpose: To evaluate a patient with acromegaly for evidence of acromegalic cardiomyopathy.
Specialty: Cardiology
Objective: laboratory tests, severity, prognosis, stage, failure handling, when to refer, failure handling and therapy escalation
ICD-10: I43.1, E22.0,